DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor

Lan Yu, Vasu Tumati, Shu Fen Tseng, Feng Ming Hsu, D. Nathan Kim, David Hong, Jer Tsong Hsieh, Corbin Jacobs, Payal Kapur, Debabrata Saha

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Radiation therapy (RT) is an effective strategy for the treatment of localized prostate cancer (PCa) as well as local invasion. However, some locally advanced cancers develop radiation resistance and recur after therapy; therefore, the development of radiation-sensitizing compounds is essential for treatment of these tumors. DOC-2/DAB2 interactive protein (DAB2IP), which is a novel member of the Ras-GTPase activating protein family and a regulator of phosphatidylinositol 3-kinase-Akt activity, is often downregulated in aggressive PCa. Our previous studies have shown that loss of DAB2IP results in radioresistance in PCa cells primarily because of accelerated DNA double-strand break (DSB) repair kinetics, robust G2/M checkpoint control, and evasion of apoptosis. A novel DNA-PKcs inhibitor NU7441 can significantly enhance the effect of radiation in DAB2IP-deficient PCa cells. This enhanced radiation sensitivity after NU7441 treatment is primarily due to delayed DNA DSB repair. More significantly, we found that DAB2IP-deficient PCa cells show dramatic induction of autophagy after treatment with radiation and NU7441. However, restoring DAB2IP expression in PCa cells resulted in decreased autophagy-associated proteins, such as LC3B and Beclin 1, as well as decreased phosphorylation of S6K and mammalian target of rapamycin (mTOR). Furthermore, the presence of DAB2IP in PCa cells can lead to more apoptosis in response to combined treatment of NU7441 and ionizing radiation. Taken together, NU7441 is a potent radiosensitizer in aggressive PCa cells and DAB2IP plays a critical role in enhancing PCa cell death after combined treatment with NU7441 and radiation.

Original languageEnglish (US)
Pages (from-to)1203-1212
Number of pages10
JournalNeoplasia (United States)
Volume14
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Autophagy
Prostatic Neoplasms
Radiation
DNA
Proteins
Therapeutics
Double-Stranded DNA Breaks
ras GTPase-Activating Proteins
Phosphatidylinositol 3-Kinase
Apoptosis
Radiation Tolerance
Radiation Effects
Sirolimus
Ionizing Radiation
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one
Neoplasms
Cell Death
Radiotherapy
Down-Regulation
Phosphorylation

ASJC Scopus subject areas

  • Cancer Research

Cite this

DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor. / Yu, Lan; Tumati, Vasu; Tseng, Shu Fen; Hsu, Feng Ming; Kim, D. Nathan; Hong, David; Hsieh, Jer Tsong; Jacobs, Corbin; Kapur, Payal; Saha, Debabrata.

In: Neoplasia (United States), Vol. 14, No. 12, 12.2012, p. 1203-1212.

Research output: Contribution to journalArticle

Yu, Lan ; Tumati, Vasu ; Tseng, Shu Fen ; Hsu, Feng Ming ; Kim, D. Nathan ; Hong, David ; Hsieh, Jer Tsong ; Jacobs, Corbin ; Kapur, Payal ; Saha, Debabrata. / DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor. In: Neoplasia (United States). 2012 ; Vol. 14, No. 12. pp. 1203-1212.
@article{67cc8a519aaa49948a8b03b7011d0713,
title = "DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor",
abstract = "Radiation therapy (RT) is an effective strategy for the treatment of localized prostate cancer (PCa) as well as local invasion. However, some locally advanced cancers develop radiation resistance and recur after therapy; therefore, the development of radiation-sensitizing compounds is essential for treatment of these tumors. DOC-2/DAB2 interactive protein (DAB2IP), which is a novel member of the Ras-GTPase activating protein family and a regulator of phosphatidylinositol 3-kinase-Akt activity, is often downregulated in aggressive PCa. Our previous studies have shown that loss of DAB2IP results in radioresistance in PCa cells primarily because of accelerated DNA double-strand break (DSB) repair kinetics, robust G2/M checkpoint control, and evasion of apoptosis. A novel DNA-PKcs inhibitor NU7441 can significantly enhance the effect of radiation in DAB2IP-deficient PCa cells. This enhanced radiation sensitivity after NU7441 treatment is primarily due to delayed DNA DSB repair. More significantly, we found that DAB2IP-deficient PCa cells show dramatic induction of autophagy after treatment with radiation and NU7441. However, restoring DAB2IP expression in PCa cells resulted in decreased autophagy-associated proteins, such as LC3B and Beclin 1, as well as decreased phosphorylation of S6K and mammalian target of rapamycin (mTOR). Furthermore, the presence of DAB2IP in PCa cells can lead to more apoptosis in response to combined treatment of NU7441 and ionizing radiation. Taken together, NU7441 is a potent radiosensitizer in aggressive PCa cells and DAB2IP plays a critical role in enhancing PCa cell death after combined treatment with NU7441 and radiation.",
author = "Lan Yu and Vasu Tumati and Tseng, {Shu Fen} and Hsu, {Feng Ming} and Kim, {D. Nathan} and David Hong and Hsieh, {Jer Tsong} and Corbin Jacobs and Payal Kapur and Debabrata Saha",
year = "2012",
month = "12",
doi = "10.1593/neo.121310",
language = "English (US)",
volume = "14",
pages = "1203--1212",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor

AU - Yu, Lan

AU - Tumati, Vasu

AU - Tseng, Shu Fen

AU - Hsu, Feng Ming

AU - Kim, D. Nathan

AU - Hong, David

AU - Hsieh, Jer Tsong

AU - Jacobs, Corbin

AU - Kapur, Payal

AU - Saha, Debabrata

PY - 2012/12

Y1 - 2012/12

N2 - Radiation therapy (RT) is an effective strategy for the treatment of localized prostate cancer (PCa) as well as local invasion. However, some locally advanced cancers develop radiation resistance and recur after therapy; therefore, the development of radiation-sensitizing compounds is essential for treatment of these tumors. DOC-2/DAB2 interactive protein (DAB2IP), which is a novel member of the Ras-GTPase activating protein family and a regulator of phosphatidylinositol 3-kinase-Akt activity, is often downregulated in aggressive PCa. Our previous studies have shown that loss of DAB2IP results in radioresistance in PCa cells primarily because of accelerated DNA double-strand break (DSB) repair kinetics, robust G2/M checkpoint control, and evasion of apoptosis. A novel DNA-PKcs inhibitor NU7441 can significantly enhance the effect of radiation in DAB2IP-deficient PCa cells. This enhanced radiation sensitivity after NU7441 treatment is primarily due to delayed DNA DSB repair. More significantly, we found that DAB2IP-deficient PCa cells show dramatic induction of autophagy after treatment with radiation and NU7441. However, restoring DAB2IP expression in PCa cells resulted in decreased autophagy-associated proteins, such as LC3B and Beclin 1, as well as decreased phosphorylation of S6K and mammalian target of rapamycin (mTOR). Furthermore, the presence of DAB2IP in PCa cells can lead to more apoptosis in response to combined treatment of NU7441 and ionizing radiation. Taken together, NU7441 is a potent radiosensitizer in aggressive PCa cells and DAB2IP plays a critical role in enhancing PCa cell death after combined treatment with NU7441 and radiation.

AB - Radiation therapy (RT) is an effective strategy for the treatment of localized prostate cancer (PCa) as well as local invasion. However, some locally advanced cancers develop radiation resistance and recur after therapy; therefore, the development of radiation-sensitizing compounds is essential for treatment of these tumors. DOC-2/DAB2 interactive protein (DAB2IP), which is a novel member of the Ras-GTPase activating protein family and a regulator of phosphatidylinositol 3-kinase-Akt activity, is often downregulated in aggressive PCa. Our previous studies have shown that loss of DAB2IP results in radioresistance in PCa cells primarily because of accelerated DNA double-strand break (DSB) repair kinetics, robust G2/M checkpoint control, and evasion of apoptosis. A novel DNA-PKcs inhibitor NU7441 can significantly enhance the effect of radiation in DAB2IP-deficient PCa cells. This enhanced radiation sensitivity after NU7441 treatment is primarily due to delayed DNA DSB repair. More significantly, we found that DAB2IP-deficient PCa cells show dramatic induction of autophagy after treatment with radiation and NU7441. However, restoring DAB2IP expression in PCa cells resulted in decreased autophagy-associated proteins, such as LC3B and Beclin 1, as well as decreased phosphorylation of S6K and mammalian target of rapamycin (mTOR). Furthermore, the presence of DAB2IP in PCa cells can lead to more apoptosis in response to combined treatment of NU7441 and ionizing radiation. Taken together, NU7441 is a potent radiosensitizer in aggressive PCa cells and DAB2IP plays a critical role in enhancing PCa cell death after combined treatment with NU7441 and radiation.

UR - http://www.scopus.com/inward/record.url?scp=84871550160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871550160&partnerID=8YFLogxK

U2 - 10.1593/neo.121310

DO - 10.1593/neo.121310

M3 - Article

VL - 14

SP - 1203

EP - 1212

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 12

ER -